PAPER Zampieri G, Cabrol L, Urra C, Castro-Nallar E, Schwob G, Cleary D, Angione C, Deacon RM, Hurley MJ, Cogram P
SEARCH RESULTS
336874 RESULTS
PAPER Rubin R
A Blood Test for Alzheimer Disease, Repurposing GLP-1s, and Wildfire Smoke-Highlights From the AAIC.
JAMA. 2024 Aug 16; PubMed.PAPER Visansirikul S, Yanaso S, Boondam Y, Prasittisa K, Prutthiwanasan B, Chongruchiroj S, Sripha K
Discovery of novel coumarin triazolyl and phenoxyphenyl triazolyl derivatives targeting amyloid beta aggregation-mediated oxidative stress and neuroinflammation for enhanced neuroprotection.
RSC Med Chem. 2024 Aug 14;15(8):2745-2765. Epub 2024 Jun 21 PubMed.PAPER Rangasamy SB, Jana M, Dasarathi S, Kundu M, Pahan K
Corrigendum to "Treadmill workout activates PPARα in the hippocampus to upregulate ADAM10, decrease plaques and improve cognitive functions in 5XFAD mouse model of Alzheimer's disease" [Brain Behav. Immun. 109 (2023) 204-218].
Brain Behav Immun. 2024 Aug 15; PubMed.PAPER Ramirez KA, Gigliotti C, Little EA, Peavy GM, Evans C, Paredes AM, Pacheco-Cole L, Zlatar ZZ, Jacobs DM, Gollan TH, González HM, Soria-Lopez JA, Huisa BN, Brewer JB, Galasko D, Salmon DP
Overcoming Barriers to Latino Participation in Alzheimer's Disease Research.
Int J Aging Hum Dev. 2024 Aug 16;:914150241268259. PubMed.PAPER Li W, Guo Q
Comment on: Impaired Retinal Capillary Function in Patients With Alzheimer Disease.
J Neuroophthalmol. 2024 Aug 16; PubMed.PAPER Cipolla JA, Jiang H, Simms AG, Baumel BS, Rundek T, Wang J
Impaired Retinal Capillary Function in Patients With Alzheimer Disease: Response.
J Neuroophthalmol. 2024 Aug 16; PubMed.Investigating Mitochondrial-Nuclear Communication in AD/ADRD (R01 Clinical Trial Not Allowed) (RFA-AG-25-026)
GRANT Friday, August 16, 2024- 10:00pm National Institute on Aging Letter of Intent due October 7, 2024. Application due November 07, 2024. https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-25-026.html 08 Nov 2024
Clinical Trials Addressing Unmet Needs of Rare Neurodegenerative Diseases (R01) Clinical Trials Required (RFA-FD-25-001)
GRANT Friday, August 16, 2024- 10:00pm U.S. Food and Drug Administration 2024 dates: LOI due September 22, 2024; application due October 22, 2024. 2025 dates: LOI due September 21, 2025; application due October 21, 2025. https://grants.nih.gov/grants/guide/rfa-
Optimization of Genome Editing Therapeutics for Alzheimer's Disease-Related Dementias (ADRD) (U01- Clinical Trials Not Allowed) (RFA-NS-24-037)
GRANT Friday, August 16, 2024- 10:00pm National Institute of Neurological Disorders and Stroke, National Institute on Aging Application budgets are limited to no more than $1,000,000 in direct costs per year. The maximum project period is five years. November 1
Notice of Intent to Publish a Funding Opportunity Announcement for Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional) (NOT-NS-24-014)
GRANT Friday, August 16, 2024- 9:45pm National Institutes of Health Estimated Publication Date of Notice of Funding Opportunity: October 01, 2024. First Estimated Application Due Date: January 27, 2025. https://grants.nih.gov/grants/guide/notice-files/NOT-NS-24
Notice of Intent to Publish a Funding Opportunity Announcement for Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional) (NOT-NS-24-015)
GRANT Friday, August 16, 2024- 9:45pm National Institutes of Health Estimated Publication Date of Notice of Funding Opportunity: October 01, 2024. First Estimated Application Due Date: January 27, 2025. https://grants.nih.gov/grants/guide/notice-files/NOT-NS-24
PAPER Li S, Wang Z, Liu G, Chen M
Neurodegenerative diseases and catechins: (-)-epigallocatechin-3-gallate is a modulator of chronic neuroinflammation and oxidative stress.
Front Nutr. 2024;11:1425839. Epub 2024 Aug 1 PubMed.PAPER Skuladottir AT, Tragante V, Sveinbjornsson G, Helgason H, Sturluson A, Bjornsdottir A, Jonsson P, Palmadottir V, Sveinsson OA, Jensson BO, Gudjonsson SA, Ivarsdottir EV, Gisladottir RS, Gunnarsson AF, Walters GB, Jonsdottir GA, Thorgeirsson TE, Bjornsdottir G, Holm H, Gudbjartsson DF, Sulem P, Stefansson H, Stefansson K
Loss-of-function variants in ITSN1 confer high risk of Parkinson's disease.
NPJ Parkinsons Dis. 2024 Aug 15;10(1):140. PubMed.PAPER Ilardi CR, Menichelli A, Michelutti M, Cattaruzza T, Federico G, Salvatore M, Iavarone A, Manganotti P
On the Clinimetrics of the Montreal Cognitive Assessment: Cutoff Analysis in Patients with Mild Cognitive Impairment due to Alzheimer's Disease.
J Alzheimers Dis. 2024 Aug 12; PubMed.Current Filters
No filters selected